PF-Atlas › Clinical Trials › NCT02412020

Treatment of Refractory Chronic Cough With PA101

PA101 · Phase 2

Registry ID

NCT02412020

Phase

Phase 2

Status

Completed

Drug / intervention

PA101

Sponsor

Patara Pharma

Start

2015-02

Enrollment

Locations

About this trial

This is a double-blind, randomized, placebo-controlled, 2-period crossover, 2-cohort study in adult patients with refractory chronic cough. The purpose of the study is to assess the efficacy and safety of inhaled PA101 delivered via eFlow high efficiency nebulizer for treating refractory chronic cough.

View NCT02412020 on ClinicalTrials.gov →

Explore related

All PA101 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT02412020 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.